Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanitha S Raman

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Science Translational Medicine|July 29, 2011
Targeting TLRs expands the antibody repertoire in response to a malaria vaccineSteven R Wiley, Vanitha S Raman, Anthony Desbien, et al.
Clinical and Vaccine Immunology : CVI|June 3, 2011
KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisYasuyuki Goto, Ajay Bhatia, Vanitha S Raman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2010
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasisVanitha S Raman, Ajay Bhatia, Alex Picone, et al.
Vaccine|August 15, 2009
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsionSusan L Baldwin, Narek Shaverdian, Yasuyuki Goto, et al.
Infection and Immunity|August 29, 2007
Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse earMalcolm S Duthie, Stephen T Reece, Ramanuj Lahiri, et al.
The Journal of Experimental Medicine|January 7, 2004
BCMA is essential for the survival of long-lived bone marrow plasma cellsBrian P O'Connor, Vanitha S Raman, Loren D Erickson, et al.
Vaccine|December 12, 2012
Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosyMalcolm S Duthie, Lucas H Sampaio, Regiane M Oliveira, et al.
Plos One|November 10, 2010
A synthetic adjuvant to enhance and expand immune responses to influenza vaccinesRhea N Coler, Susan L Baldwin, Narek Shaverdian, et al.
Vaccine|February 26, 2011
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateSusana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, et al.
Clinical & Translational Immunology|July 16, 2015
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Science Translational Medicine|July 29, 2011
Targeting TLRs expands the antibody repertoire in response to a malaria vaccineSteven R Wiley, Vanitha S Raman, Anthony Desbien, et al.
Clinical and Vaccine Immunology : CVI|June 3, 2011
KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisYasuyuki Goto, Ajay Bhatia, Vanitha S Raman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2010
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasisVanitha S Raman, Ajay Bhatia, Alex Picone, et al.
Vaccine|August 15, 2009
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsionSusan L Baldwin, Narek Shaverdian, Yasuyuki Goto, et al.
Infection and Immunity|August 29, 2007
Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse earMalcolm S Duthie, Stephen T Reece, Ramanuj Lahiri, et al.
The Journal of Experimental Medicine|January 7, 2004
BCMA is essential for the survival of long-lived bone marrow plasma cellsBrian P O'Connor, Vanitha S Raman, Loren D Erickson, et al.
Vaccine|December 12, 2012
Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosyMalcolm S Duthie, Lucas H Sampaio, Regiane M Oliveira, et al.
Plos One|November 10, 2010
A synthetic adjuvant to enhance and expand immune responses to influenza vaccinesRhea N Coler, Susan L Baldwin, Narek Shaverdian, et al.
Vaccine|February 26, 2011
A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidateSusana Lousada-Dietrich, Prajakta S Jogdand, Søren Jepsen, et al.
Clinical & Translational Immunology|July 16, 2015
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.
Pageof 2